Congratulations to the 3 finalists who will present the following technologies:

Inflammatix logo
The HostDxTM Sepsis test evaluates the patient (“host”) response to better diagnose acute infections and sepsis. The test reveals acute infection or sepsis where pathogens have NOT entered the bloodstream or aren’t detectable, which is the case for most patients. The expression levels of 29 host immune genes are measured and combined by clinically validated advanced proprietary algorithms to inform on the likelihood of a bacterial infection, the separate likelihood of a viral infection, and the infection’s severity (e.g. 30-day mortality risk). The HostDx Sepsis test will be performed on a point-of-care sample-to-answer diagnostic instrument in under 30 minutes.

PixCell_logo new
PixCell's disruptive lab-on-cartridge and artificial intelligence technology offers a paradigm shift in healthcare by simplifying blood tests and making high-end advanced diagnostics accessible at the point of care, thus enabling the widespread early detection of cancer, heart failure, and infection.

The Singlera Genomics ColonES test uses next-generation sequencing-based targeted methylation haplotyping of bisulfite-treated cell-free DNA for early colorectal cancer screening. Singlera Genomics applies methylation haplotype analysis to cell-free DNA for early detection of cancer, by using a highly specific and targeted methylation enrichment method using next-generation sequencing. Combining a genome-wide target screening methodology, patented methylation haplotyping technology and informatics, and an efficient and specific targeted methylation enrichment method called MethylTitan, Singlera’s ColonES assay has been shown to have 97% sensitivity for colorectal cancer (stage I) with a specificity greater than 99%.